Case−Control Study of Risk Factors for Meningococcal Disease in Chile
, Isabel Matute, Claudia González, Iris Delgado, Lucy Poffald, Elena Pedroni, Tania Alfaro, Macarena Hirmas, Manuel Nájera, Ana Gormaz, Darío López, Sergio Loayza, Catterina Ferreccio, Doris Gallegos, Rodrigo Fuentes, Pablo Vial, and Ximena Aguilera
Author affiliations: Universidad del Desarrollo, Santiago, Chile (A. Olea, I. Matute, C. González, I. Delgado, L. Poffald, M. Hirmas, M. Nájera, A. Gormaz, R. Fuentes, P. Vial, X. Aguilera); Universidad Isalud, Buenos Aires, Argentina (E. Pedroni); Universidad de Chile, Santiago (T. Alfaro); Chilean Ministry of Health, Santiago (D. López, S. Loayza, D. Gallegos); Pontificia Universidad Católica de Chile, Santiago (C. Ferreccio)
Figure. Monthly cases of meningococcal disease by serogroup, Chile 2011–2014. Dotted vertical line indicates beginning of the vaccination campaign against Neisseria meningitidis serogroups A, C, W, and Y. Data were obtained from the Department of Epidemiology, Ministry of Health of Chile.
Page created: June 19, 2017
Page updated: June 19, 2017
Page reviewed: June 19, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.